This is a Prospective, Single-arm, Multicenter, Observational Non-interventional Study (NIS) in Germany of Patient Characteristics, Usage and Effectiveness of Abrocitinib in Patients With Moderate to Severe Atopic Dermatitis (AD)

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 05 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abrocitinib (Primary)
Indications Atopic dermatitis
Focus Therapeutic Use
Sponsors Pfizer

Most Recent Events

01 Nov 2024 Status changed from recruiting to discontinued.(Business decision: Due to the slow recruitment, the sponsor decided to discontinue the study early)
26 Jun 2024 Planned End Date changed from 14 Apr 2025 to 30 Apr 2028.
26 Jun 2024 Planned primary completion date changed from 28 Feb 2025 to 31 May 2027.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight